GeoVax Explores Needle-Free Vaccine Delivery with Vaxxas Technology
GeoVax Labs, Inc. initiates a research program to evaluate the potential of a needle-free, self-administered GEO-MVA vaccine using Vaxxas' HD-MAP technology, aiming to enhance global immunization efforts.
GeoVax Labs, Inc. has announced a new research program focusing on the evaluation of its GEO-MVA vaccine delivered through Vaxxas' high-density microarray patch (HD-MAP) technology. This study, conducted at the University of Queensland, aims to assess the vaccine's immunogenicity, delivery efficiency, and thermostability in preclinical models. The HD-MAP platform offers a needle-free, skin-targeted delivery method that could significantly improve vaccine accessibility and effectiveness, especially in low- and middle-income countries.
The initiative represents a strategic move by GeoVax to expand the applicability of its MVA vaccine platform, addressing global needs for more accessible and ruggedized vaccines. David Dodd, Chairman and CEO of GeoVax, highlighted the potential of this technology to enable more potent immune responses at lower doses, eliminate the need for needles, and enhance vaccine thermostability. These features could be particularly beneficial for routine immunization and rapid deployment during outbreaks.
Advantages of the HD-MAP platform over traditional needle-and-syringe delivery include the possibility of self-administration, increased patient acceptance, higher immunogenicity, reduced reliance on cold chain storage, and faster deployment in emergency settings. The Vaxxas HD-MAP platform has already shown promise in enhancing immunogenicity in various studies, and GeoVax's recent favorable scientific advice from the European Medicines Agency (EMA) supports a streamlined regulatory pathway for the GEO-MVA vaccine.
This research program underscores GeoVax's commitment to advancing vaccine technology to meet global health challenges, with the potential to revolutionize vaccine delivery and accessibility worldwide.